Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 4,000 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 4,000 shares of the stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $434.88, for a total transaction of $1,739,520.00. Following the sale, the chief executive officer owned 130 shares of the company’s stock, valued at approximately $56,534.40. This represents a 96.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $453.07 on Friday. The firm’s fifty day moving average is $356.31 and its two-hundred day moving average is $319.01. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $455.12. The firm has a market cap of $20.44 billion, a PE ratio of 17.68, a P/E/G ratio of 6.76 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). The company had revenue of $798.60 million for the quarter, compared to analysts’ expectations of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business’s quarterly revenue was up 11.7% compared to the same quarter last year. During the same period in the prior year, the business earned $5.85 EPS. Research analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Weiss Ratings reiterated a “hold (c+)” rating on shares of United Therapeutics in a research note on Saturday, September 27th. Jefferies Financial Group lifted their price objective on shares of United Therapeutics from $432.00 to $564.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. JPMorgan Chase & Co. dropped their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 8th. Royal Bank Of Canada began coverage on shares of United Therapeutics in a research note on Friday, September 26th. They issued an “outperform” rating and a $569.00 target price for the company. Finally, Bank of America lifted their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the company a “neutral” rating in a report on Tuesday, September 2nd. Ten investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $449.57.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Chung Wu Investment Group LLC acquired a new stake in shares of United Therapeutics during the 2nd quarter valued at approximately $29,000. WealthCollab LLC increased its stake in United Therapeutics by 55.9% in the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. raised its holdings in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after purchasing an additional 46 shares during the last quarter. SVB Wealth LLC purchased a new stake in United Therapeutics during the first quarter worth $32,000. Finally, Geneos Wealth Management Inc. grew its holdings in United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the last quarter. 94.08% of the stock is owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.